SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 11.3% Stake in Allogene Therapeutics
Beneficial Ownership Disclosure
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, revealing a beneficial ownership of 11.3% of Allogene Therapeutics Inc.'s common stock as of December 31, 2024.
Summary
- FMR LLC and Abigail P. Johnson collectively beneficially own 23,771,994.81 shares of Allogene Therapeutics Inc. common stock.
- This ownership represents 11.3% of the total outstanding common stock of Allogene Therapeutics Inc.
- FMR LLC holds sole voting power over 23,771,409.00 shares and sole dispositive power over 23,771,994.81 shares.
- Abigail P. Johnson holds sole dispositive power over 23,771,994.81 shares, with no sole or shared voting power.
- The filing is an Amendment No. 2 to a Schedule 13G, indicating a change from a previous filing.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- Several FMR LLC subsidiaries and affiliates, including Fidelity Management & Research Company LLC, FIAM LLC, Fidelity Management Trust Company, and Strategic Advisers LLC, are involved in the beneficial ownership.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or prospects.
Positives
- The disclosure of a significant institutional investment by FMR LLC, a major asset manager, can be interpreted as a vote of confidence in Allogene Therapeutics Inc.'s long-term prospects.
Risks
- The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, mitigating a potential risk of hostile takeover or activist investor intervention.
Future Outlook
NA
Industry Context
This filing indicates continued or increased institutional interest in the biotechnology or pharmaceutical sector, specifically in companies like Allogene Therapeutics Inc. It reflects a major asset manager's position in a publicly traded company.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional shareholder's stake, which can influence investor perception and potentially stock liquidity.
- Management: Awareness of a large, passive institutional holder, which typically implies less direct influence on day-to-day operations but still represents a significant voting block.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for Stephanie J. Brown on behalf of FMR LLC. |
| 2023-01-10 | Date of Schedule 13G filing by FMR LLC, accession number -23-000003, referenced for Power of Attorney. |
| 2023-01-26 | Effective date of Power of Attorney for Stephanie J. Brown on behalf of Abigail P. Johnson. |
| 2023-01-31 | Date of Schedule 13G filing by FMR LLC, accession number -23-000038, referenced for Abigail P. Johnson's Power of Attorney. |
| 2024-12-31 | Date of event which requires filing of this statement (ownership stake determination date). |
| 2025-02-11 | Date of signing and filing of this Schedule 13G Amendment No. 2. |
Keywords
Allogene Therapeutics Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Biotechnology, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.